Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 165 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple... July 28, 2022 Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... August 20, 2024 Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... February 9, 2023 How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 Load more HOT NEWS New insights on self-sampling for cervical cancer screening Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast... Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL...
